Uncategorized

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Medivir AB announces that a poster entitled ‘A triple combination of fostrox with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo,’ will be presented at the American Association for Cancer Research Annual Meeting by Fredrik Öberg, CSO at Medivir.

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination Read More »

Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst

CathVision announced initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity™ algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.1 The first patient has been enrolled.

Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst Read More »

Scroll to Top